USA – Eli Lilly has formed a multi-year collaboration with China-based Regor Therapeutics Group to discover and develop new therapies for metabolic disorders in a deal that will see the…
Read MoreLilly bags a license worth US$1.5 billion for a batch of metabolic candidates with Regor Therapeutics
